Ep203: Sri Kosuri on Small Molecule Correctors of Disease
Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistraf...
Radio and PodcastLive Radio & Podcasts
"The Long Run" Antarctic explorer Ernest Shackleton, if he were alive, would appreciate biotech. Today’s scientific entrepreneurs must be ready for the “hazardous journey, bitter cold, long...
Listen to The Long Run with Luke Timmerman, a Science & Medicine podcast by The Long Run with Luke Timmerman. Stream 201 episodes in English, follow new audio stories, and play episodes online on Radio and Podcast.
Browse this show under Science & Medicine podcasts.
20 episodes are loaded now from a catalog of 201. More episodes can be opened from this page.
Explore Science & Medicine podcasts, Sweden podcasts and English podcasts.
Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistraf...
Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reimagining biology to take advantage o...
Jeremy Levin, executive chair of Ovid Therapeutics, discusses his new book "Biotech in the Balance: Saving a Strategic Industry in an Age of...
Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders a...
Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis...
Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.
Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.
Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.
Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report
Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live health...
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sano...
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycy...
Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.
Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.
Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new...
Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely av...
Jen Adair, professor and associate director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School, on crea...